Clinical oncology最新文献

英文中文

Variation in UK Oesophageal Radiotherapy Practice - Cause for Concern or Opportunity for Harmonisation? 英国食道放射治疗实践的变化-引起关注还是协调的机会？

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-04-01 Epub Date: 2026-01-24 DOI: 10.1016/j.clon.2026.104065

K. Sabzevari , C. Brunner , O. Nicholas , T.D.L. Crosby , S. Gwynne

引用次数: 0

Dual Checkpoint Blockade of CTLA-4 and PD-1 Overcomes Low–Tumour Mutational Burden Resistance CTLA-4和PD-1的双检查点阻断克服低肿瘤突变负荷抵抗

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-04-01 Epub Date: 2026-01-23 DOI: 10.1016/j.clon.2026.104061

M. Zheng

引用次数: 0

Factors Affecting Treatment Resilience in Patients With Oesophago-gastric Cancers Undergoing Palliative Chemotherapy: A Rapid Review 影响食管癌-胃癌姑息性化疗患者治疗恢复力的因素：快速回顾。

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-03-01 Epub Date: 2025-10-25 DOI: 10.1016/j.clon.2025.103963

K. Datta , A. Byrne , D. Holland-Hart

Aims

Oesophago-gastric cancers are the fifth most common in the UK. Most patients present with advanced disease and are unsuitable for curative surgery, instead receiving palliative treatment to improve prognosis and symptom burden. Treatment resilience refers to the ability of patients to tolerate their anti-cancer treatment. Palliative chemotherapy can result in significant toxicity; almost 40% of patients are unable to complete their chemotherapy regimen, with this proportion rising significantly in older and frailer patients. Despite most cases occurring in patients over 70, older and frailer patients are often excluded from clinical trials, resulting in limited evidence to guide which patients are most likely to benefit from palliative chemotherapy. This review therefore aimed to appraise evidence regarding treatment resilience to guide clinicians in identifying the most suitable candidates for palliative chemotherapy.

Materials and Methods

This study was conducted using modified systematic methods. Search results were limited to articles from the last 10 years. Pretreatment characteristics influencing treatment resilience were assessed, as measured by completion rates, dose reductions and toxicities.

Results

Of the 931 papers returned, 14 reports of 13 studies were included in this review. Factors assessed included age, performance status, frailty, lymphopenia and sarcopenia. Frailty and body composition appear potentially reliable indicators of chemotherapy toxicity. Poor performance status may be a possible indicator of treatment non-completion. There was no clear relationship between treatment resilience and age or lymphopenia.

Conclusion

Although this review was unable to specify patient characteristics to reliably predict patient tolerance of palliative chemotherapy, potential factors were identified. Future research should focus on prospective investigation of these factors to support a precision medicine algorithmic approach by multidisciplinary teams in assessing treatment resilience. Age should not necessarily be a barrier to receiving chemotherapy. Decisions regarding palliative treatment may be guided by these factors as well as patient preference.

目的：食道-胃癌是英国第五大常见癌症。多数患者病情发展到晚期，不适合进行根治性手术，转而接受姑息性治疗，以改善预后和减轻症状负担。治疗弹性是指患者对抗癌治疗的耐受能力。姑息性化疗可导致明显的毒性；几乎40%的患者无法完成化疗方案，这一比例在老年和虚弱患者中显著上升。尽管大多数病例发生在70岁以上的患者中，但老年人和体弱多病的患者往往被排除在临床试验之外，导致指导哪些患者最有可能从姑息性化疗中受益的证据有限。因此，本综述旨在评估有关治疗恢复力的证据，以指导临床医生确定最适合姑息性化疗的候选人。材料和方法：本研究采用改进的系统方法进行。搜索结果仅限于最近10年的文章。通过完成率、剂量减少和毒性来评估影响治疗恢复力的预处理特性。结果：在收到的931篇论文中，13项研究的14篇报告被纳入本综述。评估的因素包括年龄、运动状态、虚弱、淋巴细胞减少和肌肉减少。虚弱和身体成分似乎是化疗毒性的潜在可靠指标。不良的表现状态可能是治疗未完成的一个可能的指标。治疗恢复力与年龄或淋巴细胞减少之间没有明确的关系。结论：虽然这篇综述不能明确患者的特征来可靠地预测患者对姑息性化疗的耐受性，但确定了潜在的因素。未来的研究应侧重于对这些因素的前瞻性调查，以支持多学科团队在评估治疗弹性时采用精确医学算法方法。年龄不一定是接受化疗的障碍。关于姑息治疗的决定可能会受到这些因素以及患者偏好的指导。

{"title":"Factors Affecting Treatment Resilience in Patients With Oesophago-gastric Cancers Undergoing Palliative Chemotherapy: A Rapid Review","authors":"K. Datta , A. Byrne , D. Holland-Hart","doi":"10.1016/j.clon.2025.103963","DOIUrl":"10.1016/j.clon.2025.103963","url":null,"abstract":"<div><h3>Aims</h3><div>Oesophago-gastric cancers are the fifth most common in the UK. Most patients present with advanced disease and are unsuitable for curative surgery, instead receiving palliative treatment to improve prognosis and symptom burden. Treatment resilience refers to the ability of patients to tolerate their anti-cancer treatment. Palliative chemotherapy can result in significant toxicity; almost 40% of patients are unable to complete their chemotherapy regimen, with this proportion rising significantly in older and frailer patients. Despite most cases occurring in patients over 70, older and frailer patients are often excluded from clinical trials, resulting in limited evidence to guide which patients are most likely to benefit from palliative chemotherapy. This review therefore aimed to appraise evidence regarding treatment resilience to guide clinicians in identifying the most suitable candidates for palliative chemotherapy.</div></div><div><h3>Materials and Methods</h3><div>This study was conducted using modified systematic methods. Search results were limited to articles from the last 10 years. Pretreatment characteristics influencing treatment resilience were assessed, as measured by completion rates, dose reductions and toxicities.</div></div><div><h3>Results</h3><div>Of the 931 papers returned, 14 reports of 13 studies were included in this review. Factors assessed included age, performance status, frailty, lymphopenia and sarcopenia. Frailty and body composition appear potentially reliable indicators of chemotherapy toxicity. Poor performance status may be a possible indicator of treatment non-completion. There was no clear relationship between treatment resilience and age or lymphopenia.</div></div><div><h3>Conclusion</h3><div>Although this review was unable to specify patient characteristics to reliably predict patient tolerance of palliative chemotherapy, potential factors were identified. Future research should focus on prospective investigation of these factors to support a precision medicine algorithmic approach by multidisciplinary teams in assessing treatment resilience. Age should not necessarily be a barrier to receiving chemotherapy. Decisions regarding palliative treatment may be guided by these factors as well as patient preference.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 103963"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145494839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real world evidence of sacituzumab govitecan in unresectable or metastatic triple negative breast cancer sacituzumab govitecan治疗不可切除或转移性三阴性乳腺癌的现实证据

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-03-01 Epub Date: 2026-03-14 DOI: 10.1016/j.clon.2025.104018

Mohamed Sheeraz Mohamed Azhar , Oghenevwede Okuma , Yetunde Owoseni , Oyeyemi Akala , Rabia Gul , Husam Yassin , Olubukola Ayodele

引用次数: 0

A single centre, retrospective analysis of pathological complete response rates by ER status after neoadjuvant dual HER2 targeted therapy 单中心回顾性分析新辅助双重HER2靶向治疗后ER状态的病理完全缓解率

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-03-01 Epub Date: 2026-03-14 DOI: 10.1016/j.clon.2025.104014

Keti Eremeishvili , Jae-Ram Song , Catherine Harper-Wynne , Charlotte Moss

引用次数: 0

Incidence of Pneumonitis with Concurrent Trastuzumab Emtansine (T-DM1) and Radiotherapy in HER2-Positive Breast Cancer: A retrospective review her2阳性乳腺癌合并曲妥珠单抗Emtansine （T-DM1）和放疗的肺炎发病率：回顾性回顾

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-03-01 Epub Date: 2026-03-14 DOI: 10.1016/j.clon.2025.104017

Estabrak Jiad, Charlotte Westbury, Nihal Shah

引用次数: 0

Real-world timing and incidence of haematologic adverse events with adjuvant abemaciclib: Implications for clinical practice 真实世界的时间和血液学不良事件的发生率辅助阿贝马昔利布：对临床实践的影响

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-03-01 Epub Date: 2026-03-14 DOI: 10.1016/j.clon.2025.104012

Amit Samani, Roshni Dasgupta, Yuting Gao, Samanthi Prematilaka, Dao Yi Wong, David Miles, Andreas Makris, Nihal Shah, Muhammed Baki, Stephanie Sutherland, Amy Guppy

引用次数: 0

Clinical Trials in Molecular Radiotherapy: An Overview of the Landscape 分子放射治疗的临床试验：综述

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-03-01 Epub Date: 2025-12-16 DOI: 10.1016/j.clon.2025.104003

N. Varmenot , K. Sjögreen Gleisner , J. Taprogge , G.D. Flux

In recent years the treatment of cancer with radioactive drugs, here termed molecular radiotherapy (MRT), has emerged to take a place alongside other treatment modalities, particularly non-radioactive drugs (NRDs) and external beam radiotherapy (EBRT). A purpose-built tool was developed within the Python programming environment to review the evolution of clinical trials performed in the first quarter of the century as recorded by the ClinicalTrials.gov database. It was found that the number of MRT trials registered on ClinicalTrials.gov increased by 15-fold from 6 trials in 2000 to 89 in 2024. The ratio of MRT clinical trials relative to EBRT has remained constant at approximately 1:5. Although the number of MRT trials has remained comparatively low, their frequency in relation to NRD trials has doubled over the 25-year period. All modalities have been investigated in a similar spread of early and late phase trials, with a slightly higher proportion for early phase trials in MRT. The registration of trials has increased for almost all indications, particularly for prostate, neuroendocrine and liver cancers, although the number of trials for lymphoma has declined. The diversity and number of radionuclides involved in MRT clinical trials have increased, with beta-minus emitting radionuclides accounting in 2024 for approximately 89% of studies compared to 11% for alpha-emitters.

近年来，用放射性药物治疗癌症，这里称为分子放射治疗（MRT），已经出现与其他治疗方式，特别是非放射性药物（NRDs）和外束放射治疗（EBRT）一起。我们在Python编程环境中开发了一个专门的工具，用于回顾临床试验在本世纪前25年的发展，这些临床试验记录在ClinicalTrials.gov数据库中。研究发现，在ClinicalTrials.gov上注册的MRT试验数量从2000年的6个增加到2024年的89个，增长了15倍。MRT临床试验相对于EBRT的比例一直保持不变，约为1:5。尽管MRT试验的数量仍然相对较低，但与NRD试验相比，MRT试验的频率在25年期间翻了一番。在早期和晚期试验的相似分布中对所有模式进行了调查，MRT早期试验的比例略高。几乎所有适应症的试验注册数量都有所增加，尤其是前列腺癌、神经内分泌癌和肝癌，尽管淋巴瘤的试验数量有所下降。MRT临床试验中涉及的放射性核素的多样性和数量有所增加，到2024年，β -负排放的放射性核素约占研究的89%，而α -排放的放射性核素仅占11%。

{"title":"Clinical Trials in Molecular Radiotherapy: An Overview of the Landscape","authors":"N. Varmenot , K. Sjögreen Gleisner , J. Taprogge , G.D. Flux","doi":"10.1016/j.clon.2025.104003","DOIUrl":"10.1016/j.clon.2025.104003","url":null,"abstract":"<div><div>In recent years the treatment of cancer with radioactive drugs, here termed molecular radiotherapy (MRT), has emerged to take a place alongside other treatment modalities, particularly non-radioactive drugs (NRDs) and external beam radiotherapy (EBRT). A purpose-built tool was developed within the Python programming environment to review the evolution of clinical trials performed in the first quarter of the century as recorded by the ClinicalTrials.gov database. It was found that the number of MRT trials registered on ClinicalTrials.gov increased by 15-fold from 6 trials in 2000 to 89 in 2024. The ratio of MRT clinical trials relative to EBRT has remained constant at approximately 1:5. Although the number of MRT trials has remained comparatively low, their frequency in relation to NRD trials has doubled over the 25-year period. All modalities have been investigated in a similar spread of early and late phase trials, with a slightly higher proportion for early phase trials in MRT. The registration of trials has increased for almost all indications, particularly for prostate, neuroendocrine and liver cancers, although the number of trials for lymphoma has declined. The diversity and number of radionuclides involved in MRT clinical trials have increased, with beta-minus emitting radionuclides accounting in 2024 for approximately 89% of studies compared to 11% for alpha-emitters.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104003"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146036223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinicopathological features and outcomes of patients with adenoid cystic carcinoma of the breast in a large cancer institution: Retrospective analysis of 20 years of real-world experience 大型癌症机构乳腺腺样囊性癌患者的临床病理特征和预后：对20年真实世界经验的回顾性分析

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-03-01 Epub Date: 2026-03-14 DOI: 10.1016/j.clon.2025.104024

Susanna Slater , Myrto Kastrisiou , Mae Alghawas , Edward Phillips , Stephen Johnston , Zoe Kemp , Emma Kipps , Marina Parton , Nicholas Turner , Alicia Okines

引用次数: 0

What happened to patients eligible for POSNOC who did not enter the trial? 有资格接受POSNOC但没有参加试验的患者会发生什么？

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology

Pub Date : 2026-03-01 Epub Date: 2026-03-14 DOI: 10.1016/j.clon.2025.104016

Georgina Hanbury , Jasmine Timbres , Elinor Sawyer , Daniel Smith

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Clinical oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀